Completed PHASE1 INTERVENTIONAL 2-arm NCT03646331

Bioequivalence of Imeglimin Tablet Formulations

A Phase I, Open-label, Randomised, Single-centre, 2-way Crossover Bioequivalence Study Comparing 2 Formulations of Imeglimin After Single Oral Doses in Healthy Caucasian Subjects

Sponsor: Poxel SA

Conditions Bioequivalence

Interventions Imeglimin Imeglimin Reference product

Updated 5 times since 2018 Last updated: Jan 10, 2019 Started: Sep 3, 2018 Primary completion: Sep 27, 2018 Completion: Oct 2, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03646331, this PHASE1 trial focuses on Bioequivalence and remains completed. Sponsored by Poxel SA, it has been updated 5 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Feb 2019 — Jan 2021 [monthly]

Completed PHASE1

Status: Not Yet Recruiting → Completed
Sep 2018 — Feb 2019 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Poxel SA

Data source: Poxel SA

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom